Immune checkpoint inhibitors (ICIs), particularly programmed cell death checkpoint inhibitors (anti-programmed cell death-1 [PD1]/programmed cell death ligand 1 [PD-L1]), provide an effective treatment option for various carcinomas, including HCC (4–6). This evidence concerns the gene CD274 and carcinoma.